Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 46 clinical trials
  • 0 views
  • 20 Oct, 2021
  • 1 location
PDR001 Plus Imatinib for Metastatic or Unresectable GIST

Assuming that PDR001, an anti-PD-1 antibody, with imatinib might be effective in advanced GIST after failure of standard TKI therapies including imatinib, sunitinib, and regorafenib. In this

regorafenib
imatinib
sunitinib
metastasis
liver metastasis
  • 3 views
  • 07 Feb, 2022
  • 1 location
A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy (AXAGIST)

least of imatinib and sunitinib) in terms of progression-free survival (PFS)

anticoagulants
metastatic gastrointestinal stromal tumor (gist)
sunitinib
metastasis
measurable disease
  • 0 views
  • 25 Feb, 2022
  • 1 location
Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy (PREPARE)

The primary objective of the trial is to determine the effect of a 24-week concomitant coaching on patient reported outcomes of patients receiving standard treatment for mRCC with sunitinib or a

oophorectomy
sunitinib
hysterectomy
kinase inhibitor
measurable disease
  • 70 views
  • 27 Jan, 2022
  • 14 locations
Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors (COMBOREIN)

patients with metastatic clear cell renal cell carcinoma. Current treatments for these patients are Sunitinib, Pazopanib and Temsirolimus.

pazopanib
sunitinib
carcinoma
nephrectomy
renal neoplasm
  • 4 views
  • 04 Mar, 2022
  • 1 location
Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents (PECATI)

have progressed after at least one line of platinum-based chemotherapy for advanced disease without having received any previous immunotherapy (previous bevacizumab allowed, but not sunitinib), and not

  • 0 views
  • 19 Jun, 2022
  • 7 locations
A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments (ATEZOGIST)

failure of imatinib (disease progression),sunitinib and regorafenib (either disease progression or intolerance) In the first arm, patients will be treated with imatinib + atezolizumab (experimental

  • 0 views
  • 17 May, 2022
  • 4 locations
Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)

Funding Source - FDA OOPD FDA-approved products for patients with unresectable or metastatic GIST include therapies such as imatinib and sunitinib. Although there are FDA-approved

temozolomide
imatinib
sunitinib
glioblastoma multiforme
renal function
  • 11 views
  • 12 Feb, 2022
  • 4 locations
A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)

manner. In Arm C, the efficacy and safety of sunitinib monotherapy will be evaluated as reference data.

  • 0 views
  • 23 Mar, 2022
  • 1 location
Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular Carcinoma

(of sunitinib, brivanib, linifanib, and erlotinib plus sorafenib) that did not show non-inferiority. Sorafenib, an oral multikinase inhibitor, has been the only systemic therapy demonstrated to

  • 0 views
  • 02 Jun, 2022